Stoke Therapeutics Inc. (STOK)
NASDAQ: STOKHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
STOK stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.75B
- EPS (TTM)
- -$3.81
- Dividend yield
- None
- 52-week range
- 22.05 – 40.22
- Day range
- 25.94 – 27.78
- Volume / Avg
- 615.75K / 1.02M
- Beta
- —
- Shares outstanding
- 65.41M
52-week range
STOK stock today
Shares of Stoke Therapeutics (STOK) finished lower on Nov 20 at $26.81, a drop of 0.45% or $0.12 per share, versus the S&P 500's 3.70% decline. Shares are 33.3% below their 52-week high of $40.22, set on Mar 10, 2026 and 21.6% above the 52-week low of $22.05, in the middle of the past year's range. STOK is down 15.5% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 8.6%.
Stoke Therapeutics has posted a net loss over the last twelve months (EPS of -$3.81), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Stoke Therapeutics
Company profileStoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Ian F. Smith A.C.A., C.P.A.
- Headquarters
- Bedford, MA
- Employees
- 170
- IPO year
- 2019
- Website
- stoketherapeutics.com
Financial highlights
Full financialsIn fiscal 2025, Stoke Therapeutics generated $184.4 million in revenue, up 404.5% from fiscal 2024, its 2nd consecutive year of revenue growth. Stoke Therapeutics reported a net loss of $6.9 million, compared with a loss of $89.0 million a year earlier. Operating margin was -11.2%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $184.42M | $36.55M | $8.78M | $12.40M | — |
| Growth | +404.50% | +316.34% | -29.22% | — | — |
| Net income | $-6.88M | $-88.98M | $-104.70M | $-101.07M | $-85.81M |
| EPS (diluted) | $-0.12 | $-1.65 | $-2.38 | $-2.60 | $-2.34 |
Analyst forecast
ForecastConsensus (14 analysts)
strong_buy
Avg. price target
$46.38+73.00%
- Strong buy 2
- Buy 12
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 29, 2026
- EPS actual vs est.
- $-0.65 vs $-0.88
- Surprise
- +26.14%
STOK news
All STOK news- Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business UpdatesNasdaq
- Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business UpdatesBusiness Wire
- Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial UpdatesBusiness Wire
- Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue EstimatesNasdaqSTOK, IBRX
Stoke Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ETONEton Pharmaceuticals Inc. | 60.85 | -0.83% | $1.76B | vs STOK |
| TRAXFirst Tracks Biotherapeutics Inc. | 41.64 | -6.34% | $1.75B | vs STOK |
| SDGRSchrodinger Inc. | 22.93 | -12.95% | $1.72B | vs STOK |
| ZYMEZymeworks Inc. | 26.14 | -2.68% | $1.81B | vs STOK |
| KRSAKorsana Biosciences Inc. | 37.56 | +5.95% | $1.71B | vs STOK |
| MRVIMaravai LifeSciences Holdings Inc. Class A | 6.98 | -2.92% | $1.81B | vs STOK |
| SEPNSepterna Inc. | 38.61 | -1.51% | $1.84B | vs STOK |
| VERAVera Therapeutics Inc. Class A | 25.45 | -4.86% | $1.84B | vs STOK |
Indexes, lists and sector
Stoke Therapeutics stock FAQ
What is Stoke Therapeutics's stock price today?
STOK last traded at $26.81 as of Nov 20, 4:00 PM EST, down 0.45% on the day. Prices are delayed at least 15 minutes.
Who is Stoke Therapeutics's CEO?
Mr. Ian F. Smith A.C.A., C.P.A. is the chief executive officer of Stoke Therapeutics Inc., which has about 170 employees.
What is the STOK 52-week high?
The 52-week high for STOK is $40.22 and the 52-week low is $22.05. The stock is currently 33.3% below its high.